INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Corcept Therapeutics Incorporated (CORT) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Core Viewpoint - A shareholder class action lawsuit has been filed against Corcept Therapeutics, alleging false and misleading statements regarding the clinical trials for its drug relacorilant and the likelihood of approval for its New Drug Application [1]. Group 1: Lawsuit Details - The lawsuit claims that Corcept issued false and misleading statements and failed to disclose material adverse facts related to its clinical trials [1]. - The lawsuit specifically targets shareholders who purchased Corcept's shares between October 31, 2024, and December 30, 2025, and experienced significant losses [2]. Group 2: Legal Representation - Holzer & Holzer, LLC is representing the shareholders in this class action lawsuit and has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct [3]. - The deadline for shareholders to request to be appointed as lead plaintiff in the case is April 21, 2026 [3].